Plain-English translation of NCT06145373 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing fitusiran, a new injectable medication designed to prevent bleeding in people with severe hemophilia A. The trial enrolls people who are already taking (an existing preventive treatment) and want to switch to this medication. Researchers will carefully monitor whether this medication is safe and well-tolerated when you switch from your current treatment.
People with severe hemophilia need regular preventive treatment to avoid dangerous bleeds. This trial exists to see whether this medication could be a new option for people who want an alternative to their current prevention therapy, and to ensure it works safely when you make the switch.
You likely qualify if…
You likely don't qualify if…
You will participate for up to 28 months total. First, there is a 2-month screening period, followed by a 2-month transition period where you continue your current treatment. Then you will receive the new injectable medication under your skin once a month or once every two months for up to 18 months, with clinic visits every 1–2 months. After you stop the medication, you will be monitored for about 6 months to make sure your body recovers normally, with monthly check-ups.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Taiwan